certepetide (LSTA1)
First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Key Facts
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.
View full company profileAbout Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.
View full company profileAbout Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.
View full company profileAbout Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.
View full company profileAbout Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.
View full company profileAbout Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.
View full company profileTherapeutic Areas
Other First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Pelareorep + Gemcitabine/Nab-Paclitaxel + Atezolizumab | Oncolytics Biotech | Phase 1/2 |